Peter M. Ravdin, MD, PhD, reviews the latest update of the ASCO Clinical Practice Guidelines on bisphosphonate use and bone health in women with breast cancer.
IL-17 exhibits proinflammatory properties similar to those of tumor necrosis factor-α, particularly with respect to induction of other inflammatory effectors. In addition, IL-17 synergizes potently with other cytokines, placing it in the center of the in